502 Bad Gateway

502 Bad Gateway

	COMMONWEALTH BIOTECHNOLOGIES, INC.
911 E. Leigh Street, Suite G-19, Richmond, VA 23219 800-735-9224 (800-RELY-CBI) · fax: 804-648-2641 · www.cbi-biotech.com · e-mail: [email protected]

What's new at CBI

Commonwealth Biotechnologies, Inc, is a biotechnology research and development support facility based in Richmond, Virginia. Visit the CBI Home Page to learn more about us.

October 9, 1998

Certifications Received

Commonwealth Biotechnologies, Inc. has now been registered under the Clinical Laboratories Improvement Act (CLIA) with pending accreditation by the Virginia Department of Health to perform analysis of human clinical samples for the presence of known genetic markers. Registration under the CLIA guidelines enables CBI to accept human samples for analysis.

CBI has also been inspected and received accreditation by the United States Department of Agriculture to receive bovine DNA samples from Europe to perform genetic, lineage, and identity analysis. CBI has participated in an international study to validate Bovine DNA identity testing in conjunction with a study group located in Denmark.

Previously, CBI was accredited under NFSTC guidelines (The National Forensic Science Technology Center, in St. Petersburg, Florida) to perform DNA identity testing for submission of data into the CODIS data base (Combined DNA Index System). CBI is one of only eight commercial facilities nationwide accredited by the NFSTC to perform criminal (felony) DNA database testing for submission into the FBI CODIS database.

August 12, 1998

New People

• CBI is pleased to announce that Heath Cole Knight, Ph. D., has joined our staff as a Scientist. Ms. Knight comes from the Mayo Clinic in Jacksonville, Florida and brings over ten years of experience in Human Genetics and molecular diagnostics.
• Brandon Mears was recently promoted to Laboratory Specialist.

New Contracts

• CBI has signed a contract with Strategic Diagnostics, Inc (Newark, DE) for gene synthesis and overexpression.
• The Centers for Disease Control, Atlanta, GA, has awarded CBI the second year of a five year extended contract to provide a broad panel of DNA sequencing services.

New Licenses

• CBI has negotiated a limited license with Perceptive Biosystems, Inc. for the synthesis of Protein-Nucleic Acids (PNAs).
• CBI has acquired a license from Roche Molecular Systems for use of the Polymerase Chain Reaction (PCR) technology in human identity, paternity, and diagnostic applications.
• CBI has acquired a license from Roche Molecular Systems for use of the PCR technology in veterinary diagnostic applications.
• CBI has acquired a license from PE Applied Biosystems, Inc. for use of the PCR technology for forensics and human identity applications.

Other News

Dr. Gregory A Buck, Senior Vice President and Chief Science Officer, was appointed to the External Corporate Board of the University of Virginia Training Program in Cellular and Matrix Molecular Biology, a program designed to prepare new biotechnological researchers for the 21st century. Dr. Buck was also appointed to the Special Emphasis Panel of the Tropical Medicine and Parasitology Study Group at the National Institutes of Health. This study group prioritizes research proposals, focusing on molecular studies of important tropical and parasitological diseases, for funding from the National Institutes of Health.

New Facilities

Construction of CBI's new building has started. The floor slab has been poured and the roof erected. The building is slated for occupancy in late 1998. Here is an artist's rendition of the building:

July 20, 1998

People

We are pleased to announce the following additions to our staff:

• Kris Kralovich, M.S., comes to CBI from the University of Virginia in Charlottesville. Ms. Kralovich, Senior Laboratory Specialist, is also assuming responsibilities as Laboratory Coordinator.
• Ms. Carolyn Meador joins the DNA sequence analysis group at CBI as Laboratory Technician, Advanced. Ms. Meador was most recently a veterinarian's assistant in Churchville, MD.
• Mr. Matt Robers comes to CBI from the University of Wisconsin, Madison, as a Laboratory Technician, Advanced and joins the molecular biology research group.
• Mr. Niraj Bhatt, currently enrolled in an MBA program at Virginia Commonwealth University, joins CBI part-time as a Laboratory Aide.
• Ms. Vada Rhoads, formerly of Aetna US Healthcare, joins CBI as an Office Services Specialist with an emphasis in marketing.

New Contracts

• CBI was recently awarded a Phase I Small Business Innovative Research Award from the National Institutes of Health for studies related to the rapid and specific detection of Botulism toxin in foodstuffs.
• CBI has been notified that it will receive a Phase II Small Business Innovative Research Award from the United States Department of Agriculture (USDA) to further its research program in the development of a diagnostic assay for equine infectious anemia.
• CBI has also executed research contracts with BRFF (Ijamsville, MD), Antex Biologics (Gaithersburg, MD), and Axo Diagnostics (Gaithersburg, MD).

Other News

• CBI is the named co-inventor on U.S. Patent 5,759,515, issued to Rho Med, Inc (Albuquerque, NM) on June 2, 1998. The invention, entitled "Polyvalent peptide pharmaceutical applications", describes the use of various peptide sequences in imaging diagnostics. CBI partnered with RhoMed to develop the concepts and provided the compounds which formed the basis for this patent.
• Dr. Robert B. Harris, President of CBI, has been named to the Scientific Advisory Board of NRx Biotech (Chicago, IL), a biotech start-up company whose aim is to exploit proprietary technologies which address the underlying mechanisms of neurological disorders, including brain tumors, stroke, Alzheimer's disease, loss of memory capacity due to aging, and related abnormalities

April 7, 1998

The U.S. Patent Office issued a Notice of Allowance for Patent #08/660,592 on March 3, 1998 to Commonwealth Biotechnologies Inc (CBI) for development of new heparin binding peptide compounds. During open heart surgery, the intense blood thinning effects of heparin must be reversed to restore normal blood clotting at the end of the procedure. Protamine, the only available antidote, causes frequent toxic side effects. Protamine is the only compound currently approved to reverse the blood-thinning effects of heparin in acute cardiovascular surgery. The lead compounds that we are developing would serve as a safer, more effective antidote for the anticoagulant effects of heparin. Read the full press release and a Reuters article about this exciting development.

February 9, 1998

People

• Dr. Darin R. Kent has joined Commonwealth Biotechnologies as a Research Scientist. Kent, formerly of Parke Davis Pharmaceutical Co., Ann Arbor, Michigan, brings expertise in organic mimetic chemistry to CBI.
• Mr. James H. Brennan, most recently of Star Tobacco and Pharmaceuticals, Petersburg, Virginia, joins CBI as Controller, and brings more than 15 years of financial management expertise to CBI.
• Mr. Robert Langford, formerly of Virginia Commonwealth University, joins CBI as Senior Information Technology Analyst.
• Ms. Karen Hall joins CBI as Executive Assistant.
• Ms. Erin Gorman was recently promoted to Lab Coordinator and Laboratory Specialist, Advanced.
• Mr. Gregory Meyers was recently promoted to Lab Specialist, Senior.
• Ms. Elizabeth Faircloth has now assumed all responsibilities as Senior Associate for Marketing and Corporate Development.

New Contracts

• CBI was recently awarded a five-year contract with the Centers for Disease Control and Prevention in Atlanta, Georgia, to perform automated DNA sequence analysis.
• CBI was awarded a new contract with Bayer Corporation, Inc., Raleigh, North Carolina, for basic molecular studies of various human plasma products.
• The University of Iowa Hospitals, Iowa City, Iowa, recently awarded CBI a contract to perform automated DNA sequence analysis.

A New Building!

CBI will be relocating to a new, state-of-the-art facility to be built in Gateway Centre, Chesterfield County, Virginia. The new $4 million facility will bring together all of CBI's operations for the first time.

Last Updated 9/28/98